Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 and high dose cytarabine in
treating patients with refractory or relapsed acute myelocytic or acute lymphocytic leukemia,
chronic myelogenous leukemia or refractory or relapsed lymphoblastic lymphoma.